Optimal Allogeneic PRP Concentration for Oocyte In Vitro Maturation in Women With PCOS

Gadjah Mada University

Status: Completed

Conditions: PCOS (Polycystic Ovary Syndrome)

Treatments: Other: PRP plasma rich platelets

Study type: Interventional

Funder types: Other

Identifiers

NCT07514234

PRP-PCOS-COHORT-UGM

Details and patient eligibility

About

In vitro maturation is a long-studied technique used to obtain mature oocytes outside the human body. However, this method can increase the risk of ovarian hyperstimulation syndrome (OHSS), particularly in patients with polycystic ovarian syndrome (PCOS). Culture media supplemented with platelet-rich plasma (PRP) has previously shown promise for improving oocyte maturation. This study examined the potential utility of allogeneic PRP supplementation to increase the maturation of germinal vesicle (GV)-stage oocytes collected from PCOS patients who underwent controlled ovarian stimulation. Supplementation with 5% PRP was found to support oocyte maturation under controlled ovarian stimulation. Further investigations are required to refine the use of PRP without controlled ovarian stimulation in clinical IVM protocols that may be beneficial for PCOS patients.

Enrollment: 15 patients

Sex: Female

Ages: 30 to 41 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Immature oocytes at the germinal vesicle (GV) stage
• Oocytes obtained from patients fulfilling clinical and laboratory diagnostic criteria for PCOS, defined by the presence of at least two of the following three characteristics: clinical hyperandrogenism and/or biochemical hyperandrogenemia, ovulatory dysfunction (oligomenorrhea or anovulation), and polycystic ovarian morphology (≥12 follicles measuring 2-9 mm in each ovary on ultrasonography)
• Oocytes collected from patients undergoing ovarian stimulation using the same ovarian stimulation protocol.
• Oocytes obtained from patients with primary infertility
• Oocytes obtained from treatment-naive patients with PCOS.

Exclusion criteria

- Oocytes obtained from patients with comorbid conditions, including cancer, congenital adrenal hyperplasia, Cushing's syndrome, premature ovarian failure (POF) or premature ovarian insufficiency, liver disorders, kidney disease, cardiovascular disease, diabetes mellitus (type 1 or type 2), and patients receiving steroid therapy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

PRP plasma rich platelets

Experimental group

Description:

An initial pilot experiment tested with PRP supplementation to address oocyte maturation

Treatment:

Other: PRP plasma rich platelets